Name (Synonyms) | Correlation |
---|
There is one clinical trial.
ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients
Description: The minimal value of the SOFA Score will be 0 and the maximal value 24 points. All-cause death is classified as the maximum score (24 points). In case of a subclinical disease progress without need for hospitalization, the SOFA score will be 0.
Measure: Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death Time: 30 daysDescription: minimum score is 0, maximum score is 24; higher score indicates poor outcome
Measure: Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score Time: 30 daysDescription: high-flow, continuous positive airway pressure therapy
Measure: Rates of non-invasive ventilation Time: 30 daysDescription: with causal relationship to stopping of ACEI/ARB therapy
Measure: Hospitalisation due to cardiac decompensation Time: 30 days